Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer

Chenyang Wang, Christopher R. King, Mitchell Kamrava, Keisuke S. Iwamoto, Allen M. Chen, Daniel Low, Patrick A. Kupelian, Michael L. Steinberg

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background and purpose: Second malignancies (SM) after external beam radiotherapy (EBRT) or brachytherapy (BT) for prostate cancer (PCa) are rare but serious sequelae. Materials and methods: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify men diagnosed with cT1-2N0M0 PCa between 1999 and 2005, who underwent EBRT, BT or radical prostatectomy (RP). Patients with time interval to second malignancy or follow-up shorter than five and two years were excluded for solid and hematopoietic SM analyses respectively. Risks for solid and hematopoietic SM were evaluated via the multivariate Fine and Gray proportional hazards model. Results: EBRT and BT resulted in similar increases in solid and hematopoietic SM compared to RP. In subgroup analysis stratified by treatment modality, only the EBRT cohort demonstrated significantly decreased solid and hematopoietic SM in years 2002-2005 compared to years 1999-2001, with adjusted-hazard ratios of 0.752 (p = 0.001) and 0.815 (p = 0.018) respectively. Conclusions: EBRT and BT resulted in statistically equivalent increase in both solid and hematopoietic SM compared to RP. EBRT in more recent years resulted in significantly decreased solid and hematopoietic SM, coinciding with increased utilization of IMRT.

Original languageEnglish (US)
JournalRadiotherapy and Oncology
DOIs
StateAccepted/In press - Oct 30 2016
Externally publishedYes

Fingerprint

Second Primary Neoplasms
Hematologic Neoplasms
Prostatic Neoplasms
Radiotherapy
Brachytherapy
Prostatectomy
Therapeutics
Proportional Hazards Models
Epidemiology
Databases

Keywords

  • Brachytherapy
  • External beam radiotherapy
  • Prostate cancer
  • Second malignancy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Wang, C., King, C. R., Kamrava, M., Iwamoto, K. S., Chen, A. M., Low, D., ... Steinberg, M. L. (Accepted/In press). Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer. Radiotherapy and Oncology. https://doi.org/10.1016/j.radonc.2017.01.009

Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer. / Wang, Chenyang; King, Christopher R.; Kamrava, Mitchell; Iwamoto, Keisuke S.; Chen, Allen M.; Low, Daniel; Kupelian, Patrick A.; Steinberg, Michael L.

In: Radiotherapy and Oncology, 30.10.2016.

Research output: Contribution to journalArticle

Wang, Chenyang ; King, Christopher R. ; Kamrava, Mitchell ; Iwamoto, Keisuke S. ; Chen, Allen M. ; Low, Daniel ; Kupelian, Patrick A. ; Steinberg, Michael L. / Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer. In: Radiotherapy and Oncology. 2016.
@article{ae206f6ec25a41d29ff603de3392c265,
title = "Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer",
abstract = "Background and purpose: Second malignancies (SM) after external beam radiotherapy (EBRT) or brachytherapy (BT) for prostate cancer (PCa) are rare but serious sequelae. Materials and methods: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify men diagnosed with cT1-2N0M0 PCa between 1999 and 2005, who underwent EBRT, BT or radical prostatectomy (RP). Patients with time interval to second malignancy or follow-up shorter than five and two years were excluded for solid and hematopoietic SM analyses respectively. Risks for solid and hematopoietic SM were evaluated via the multivariate Fine and Gray proportional hazards model. Results: EBRT and BT resulted in similar increases in solid and hematopoietic SM compared to RP. In subgroup analysis stratified by treatment modality, only the EBRT cohort demonstrated significantly decreased solid and hematopoietic SM in years 2002-2005 compared to years 1999-2001, with adjusted-hazard ratios of 0.752 (p = 0.001) and 0.815 (p = 0.018) respectively. Conclusions: EBRT and BT resulted in statistically equivalent increase in both solid and hematopoietic SM compared to RP. EBRT in more recent years resulted in significantly decreased solid and hematopoietic SM, coinciding with increased utilization of IMRT.",
keywords = "Brachytherapy, External beam radiotherapy, Prostate cancer, Second malignancy",
author = "Chenyang Wang and King, {Christopher R.} and Mitchell Kamrava and Iwamoto, {Keisuke S.} and Chen, {Allen M.} and Daniel Low and Kupelian, {Patrick A.} and Steinberg, {Michael L.}",
year = "2016",
month = "10",
day = "30",
doi = "10.1016/j.radonc.2017.01.009",
language = "English (US)",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer

AU - Wang, Chenyang

AU - King, Christopher R.

AU - Kamrava, Mitchell

AU - Iwamoto, Keisuke S.

AU - Chen, Allen M.

AU - Low, Daniel

AU - Kupelian, Patrick A.

AU - Steinberg, Michael L.

PY - 2016/10/30

Y1 - 2016/10/30

N2 - Background and purpose: Second malignancies (SM) after external beam radiotherapy (EBRT) or brachytherapy (BT) for prostate cancer (PCa) are rare but serious sequelae. Materials and methods: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify men diagnosed with cT1-2N0M0 PCa between 1999 and 2005, who underwent EBRT, BT or radical prostatectomy (RP). Patients with time interval to second malignancy or follow-up shorter than five and two years were excluded for solid and hematopoietic SM analyses respectively. Risks for solid and hematopoietic SM were evaluated via the multivariate Fine and Gray proportional hazards model. Results: EBRT and BT resulted in similar increases in solid and hematopoietic SM compared to RP. In subgroup analysis stratified by treatment modality, only the EBRT cohort demonstrated significantly decreased solid and hematopoietic SM in years 2002-2005 compared to years 1999-2001, with adjusted-hazard ratios of 0.752 (p = 0.001) and 0.815 (p = 0.018) respectively. Conclusions: EBRT and BT resulted in statistically equivalent increase in both solid and hematopoietic SM compared to RP. EBRT in more recent years resulted in significantly decreased solid and hematopoietic SM, coinciding with increased utilization of IMRT.

AB - Background and purpose: Second malignancies (SM) after external beam radiotherapy (EBRT) or brachytherapy (BT) for prostate cancer (PCa) are rare but serious sequelae. Materials and methods: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify men diagnosed with cT1-2N0M0 PCa between 1999 and 2005, who underwent EBRT, BT or radical prostatectomy (RP). Patients with time interval to second malignancy or follow-up shorter than five and two years were excluded for solid and hematopoietic SM analyses respectively. Risks for solid and hematopoietic SM were evaluated via the multivariate Fine and Gray proportional hazards model. Results: EBRT and BT resulted in similar increases in solid and hematopoietic SM compared to RP. In subgroup analysis stratified by treatment modality, only the EBRT cohort demonstrated significantly decreased solid and hematopoietic SM in years 2002-2005 compared to years 1999-2001, with adjusted-hazard ratios of 0.752 (p = 0.001) and 0.815 (p = 0.018) respectively. Conclusions: EBRT and BT resulted in statistically equivalent increase in both solid and hematopoietic SM compared to RP. EBRT in more recent years resulted in significantly decreased solid and hematopoietic SM, coinciding with increased utilization of IMRT.

KW - Brachytherapy

KW - External beam radiotherapy

KW - Prostate cancer

KW - Second malignancy

UR - http://www.scopus.com/inward/record.url?scp=85011596209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011596209&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2017.01.009

DO - 10.1016/j.radonc.2017.01.009

M3 - Article

AN - SCOPUS:85011596209

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

ER -